Discover
TVGN
Tevogen Bio Holdings Inc.
5.74
2 x 4.71
2 x 7.61
bid
ask
+
0.08
1.41%
2 @ 04:00 PM
5.90 +0.16 (2.79%)
| Ytd | -65.32% | |
| 1y | -90.59% |
5.74
day range
6.75
4.13
52 week range
71.00
| Open | 6.01 | Prev Close | 5.66 | Low | 5.74 | High | 6.75 | Mkt Cap | 24.22M |
| Vol | 35.68K | Avg Vol | 29.62K | EPS | -6.44 | P/E | N/A | Forward P/E | N/A |
| Beta | -1.03 | Short Ratio | 0.09 | Inst. Own | 3.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 8.49 | 200-d Avg | 16.98 | 1yr Est | 4.20 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-07-16 | CORBIN CAPITAL PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2024-06-11 | DESAI KIRTI | Chief Financial Officer | 9.70M | Purchase |
| 2024-02-13 | FEIKE JEFFREY L | Director | 581.77K | Stock Award(Grant) |
| 2024-10-16 | FLOMENBERG NEAL | Officer | 4.25M | Sale |
| 2024-02-13 | GOH KEOW LIN | Director | 193.92K | Stock Award(Grant) |
| 2024-02-13 | KHAN SADIQ | Officer | 969.62K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Portland Global Advisors Llc | 1.85M | 1.87M | 1.06% |
| 2024-09-29 | Polar Asset Management Partners Inc. | 1.58M | 1.59M | 0.90% |
| 2024-09-29 | Cantor Fitzgerald, L.P. | 603.69K | 609.73K | 0.34% |
| 2024-09-29 | Geode Capital Management, LLC | 344.29K | 347.73K | 0.20% |
| 2024-09-29 | Blackrock Inc. | 230.92K | 233.23K | 0.13% |
| 2024-09-29 | HGC Investment Management Inc. | 223.08K | 225.31K | 0.13% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-08-30 | Fidelity Small Cap Index Fund | 207.17K | 209.24K | 0.12% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 145.90K | 147.36K | 0.08% |
| 2024-08-30 | Vanguard Russell 2000 Index Fund | 88.04K | 88.92K | 0.05% |
| 2024-10-30 | iShares Micro Cap ETF | 63.24K | 63.87K | 0.04% |
| 2024-07-30 | Schwab Capital Trust-Small Cap Index Fund | 49.58K | 50.08K | 0.03% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 57.91K | 58.49K | 0.03% |
Split
| Split | Date |
|---|---|
| 1 : 50 | 2026-03-06 |